DDInter1846 DDInter150
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI (
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Nucleoside Analog {u} (Pharmacologic Class) includes {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) TPMT
TPMT {u} (Gene) is bound by {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Paclitaxel {u} (Compound) upregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Deferiprone {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Azathioprine
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates TPMT (Gene) and TPMT (Gene) is bound by Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Azathioprine (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel (Compound) upregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Azathioprine (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Azathioprine (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Azathioprine (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Azathioprine (Compound)